Why Is FORTE BIOSCIENCES IN Equity (FBRX) Stock Moving Today?

FBRX stock is moving sharply higher today, surging 39.3% in intraday trading after argenx announced a $2.2 billion agreement to acquire Forte Biosciences. The deal values the biotechnology company at $77 per share, a price that represents a significant premium to its recent performance and creates immediate upside for shareholders. The transaction is expected to expand argenx’s immunology pipeline through the inclusion of FB102, a first-in-class anti-CD122 antibody in development for autoimmune diseases.

What Happened

Forte Biosciences shares opened at $76.32, a 39.3% increase from the previous close of $54.78. The stock traded in a narrow range throughout the session, with a high of $76.72 and a low of $76.30. The deal with argenx, which is valued at approximately $2.2 billion, includes the addition of FB102 to argenx’s portfolio. This acquisition aligns with argenx’s strategic focus on expanding its autoimmune drug offerings and strengthening its position in the immunology space. The transaction has drawn attention from analysts and investors, with some suggesting the deal may cap near-term upside for FBRX shares.

What The Data Shows

In the last eight trading sessions, FBRX shares have risen 70.0%, from $44.99 to $76.50. The stock has traded between $9.10 and $62.46 over the past 52 weeks. Intraday volume has reached 16.6 million shares, which is 36.0 times the 3-month daily average. Unusual options activity has also been noted, with a notable put premium of $14,000 in the last 36 hours. The stock’s beta of 2.84 highlights its volatility relative to the broader market.

What To Watch

The acquisition is expected to close in the coming months, but no specific timeline has been provided. Investors should monitor the progress of the deal and any regulatory developments that could impact the transaction.